ProCE Banner Activity

Integrating SGLT2 Inhibitors Across the Spectrum of Heart Failure to Improve Hyperkalemia

Clinical Thought

Read my thoughts on the importance of integrating SGLT2 inhibitors across the heart failure spectrum.

Released: November 09, 2023

Expiration: November 09, 2024

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from AstraZeneca.

AstraZeneca

Disclosure

Primary Author

Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP

Professor of Medicine
Winters Center for Heart Failure
Baylor College of Medicine
Houston, Texas

Biykem Bozkurt, MD, PhD, FHFSA: consultant/advisor/speaker: Abbott, Abiomed, American Regent, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cardurion, Cyotkinetics, Daiichi Sankyo, Johnson & Johnson, Lantheus, Liva, Merck, Nova, Regeneron, Renovacor, Respicardia/Zoll, Roche, Sanofi-Aventis, Vifor.